Article

BCMA-targeted T-cell engager therapy induces sustained remission in immune thrombocytopenia.
Korenkov, Michael ORCID: https://orcid.org/0000-0002-2988-8483, Zuleeg, Maximilian Rudolf ORCID: https://orcid.org/0009-0002-9947-5585, Liebaert, Julian, Fregona, Vincent ORCID: https://orcid.org/0000-0003-4857-1737, Serve, Sebastian ORCID: https://orcid.org/0000-0002-9839-7119, Jesse, Julia, Böckle, Stephan Rainer ORCID: https://orcid.org/0000-0002-1783-9641, Bohl, Stephan Rainer ORCID: https://orcid.org/0000-0001-9379-3342, Damm, Frederik ORCID: https://orcid.org/0000-0001-5553-1173, Bullinger, Ulrich ORCID: https://orcid.org/0000-0002-5890-5510, Keller, Ulrich ORCID: https://orcid.org/0000-0002-8485-1958, Busse, Adrian ORCID: https://orcid.org/0000-0002-3470-6947, Schwarzer, Adrian, Albach, Fredrik ORCID: https://orcid.org/0000-0002-2697-9080, Thiele, Thomas ORCID: https://orcid.org/0000-0003-0177-6508, Haas, Simon ORCID: https://orcid.org/0000-0001-9227-2051, Krönke, Jan ORCID: https://orcid.org/0000-0002-4649-0506 and Hütter-Krönke, Marie Luise ORCID: https://orcid.org/0000-0002-4531-9889
Blood Immunology & Cellular Therapy 2 (3): 100062. September 2026